Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on small-molecule precision therapies. The company is prioritizing ELVN-001 from its BCR-ABL program and preparations for a planned pivotal trial, while exploring strategic alternatives for ELVN-002 and discontinuing its development.
As of June 30, 2026, Enliven held $895.2 million in cash, cash equivalents and marketable securities and reported total stockholders’ equity of $895.1 million, with 73,270,761 common shares outstanding as of July 28, 2026. Management states this liquidity is expected to fund operating expenses and capital needs for at least 12 months.
For the quarter ended June 30, 2026, research and development expense was $28.996 million and general and administrative expense was $8.213 million, leading to a net loss of $32.485 million (basic and diluted net loss per share $0.49). For the first half of 2026, net loss was $56.112 million, with $21.312 million of stock-based compensation. A June 2026 underwritten offering raised aggregate gross proceeds of $460.0 million via common stock and pre-funded warrants, significantly strengthening the balance sheet.
Enliven Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2026 and provided a business update. The company highlighted positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, with a 61% overall major molecular response and 48% achieving major molecular response by 24 weeks at the 80 mg once-daily dose. Earlier-line patients showed 67% overall major molecular response and 55% by 24 weeks. As of the March 10, 2026 cutoff, 161 patients had been enrolled with a median treatment duration of 35 weeks and a favorable safety and tolerability profile.
Following an End-of-Phase 1 FDA meeting, 80 mg once daily was selected as the recommended Phase 3 dose for the planned ENABLE-2 second-line and later trial in CML patients previously treated with one or more TKIs, comparing ELVN-001 to physician’s choice of ATP-competitive TKI. ELVN-001 received Fast Track Designation, and ENABLE-2 is expected to start in the second half of 2026, with further Phase 3 design details to be finalized after a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026.
Enliven reported a strong cash position, with $895.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to provide cash runway into 2030. Second-quarter 2026 research and development expenses were $29.0 million versus $21.5 million a year earlier, and general and administrative expenses were $8.2 million versus $7.1 million. Net loss for the quarter was $32.5 million, compared with $25.3 million in the second quarter of 2025, or $0.49 per share in both periods.
Enliven Therapeutics has filed a notice of proposed sale of common stock under Form 144, using Jefferies LLC as broker on NASDAQ. The filing lists multiple stock option positions in Enliven common stock, dated 08/09/2022, 02/23/2023, 02/13/2024, and 02/06/2025, each with specified amounts of common shares designated as securities to be sold.
Enliven Therapeutics CFO Benjamin Hohl reported an option exercise and related share sales on July 17, 2026. He exercised stock options covering 1,072 shares of common stock at an exercise price of $2.48 per share and sold 6,018 common shares in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. Following the exercise, he held 84,966 stock options for Enliven common stock.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 5,000 shares of common stock at $2.48 per share on July 17, 2026, then sold 5,000 shares in multiple trades at weighted average prices between $49.72 and $53.93. After the exercise, she reported directly holding 116,268 stock options. All transactions were effected under a pre-established Rule 10b5-1 trading plan adopted on October 19, 2025.
Helen Collins, a shareholder of Enliven Therapeutics, plans to sell up to 15,000 shares of common stock through Jefferies LLC, with an aggregate market value of $762,900.00. These 15,000 shares were acquired via stock options on 08/09/2022. Enliven Therapeutics had 71,000,000 common shares outstanding as of 07/17/2026; this is a baseline figure, not the amount being sold. Over the past three months, Collins sold 5,000 shares for $198,863.90 on 05/18/2026 and another 5,000 shares for $218,908.88 on 07/17/2026.
Enliven Therapeutics, Inc. director Lori Anne Kunkel reported selling a total of 10,000 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices of $50.8442 and $49.9834 per share.
According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, indicating the sales were scheduled in advance rather than timed discretionarily.
Enliven Therapeutics, Inc. reported that investment entities affiliated with OrbiMed executed open-market sales of its Common Stock. On June 22, 2026, the entities sold a combined 860,123 shares of Enliven at prices around $45–$45.38 per share.
After these transactions, one OrbiMed-affiliated fund reported 6,601,878 shares of Enliven Common Stock indirectly owned, while another reported 6,555,102 shares. The OrbiMed reporting entities and their related general partners and adviser disclaim beneficial ownership of the securities beyond any pecuniary interest.
OrbiMed Advisors LLC and affiliated entities filed Amendment No. 5 to their Schedule 13D on Enliven Therapeutics, Inc., reporting a reduction in beneficial ownership. They now report beneficial ownership of 6,774,507 Enliven common Shares, representing 9.5% of the 71,422,989 Shares outstanding as set out in the issuer’s June 12, 2026 Rule 424(b)(5) prospectus.
OPI VII holds 6,555,102 Shares, or about 9.2% of the class, while Genesis holds 219,405 Shares, or about 0.3%. On June 22, 2025, these funds and BIOG executed multiple open‑market sales at prices of $45.38 and $45.00 per Share. The filing states that the reporting persons may buy or sell additional Shares over time depending on market conditions and other factors but do not currently have specific plans for corporate control or strategic actions at the issuer.
ELVN affiliates reported proposed sales of Common Stock under Form 144, with broker-handled orders and a recent resale by a fund. Examples include OrbiMed Genesis Master Fund selling 9,086 shares on 06/15/2026 and broker entries showing 24,846 shares (Jefferies LLC). Shares outstanding were 69,822,989 as of 06/22/2026.
The filing lists broker participants and an earlier issuer-related line dated 02/23/2023 showing 26,323 shares. The notice documents proposed and recent transactions; timing and proceeds mechanics follow the sale notices provided.